Bayer Pharma

Introduction
Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest
pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business
include human and veterinary pharmaceuticals; consumer healthcare products; agricultural
chemicals, seeds, and biotechnology products. The company operates in three segments: Crop
Science, Pharmaceuticals, and Consumer Health. The Crop Science segment engages in the
development, production, and marketing of seeds, plant traits, crop protection, digital solutions, and
customer services to promote sustainable agriculture. The Pharmaceuticals segment provides
prescription products primarily for cardiology and women's health, specialty therapeutics in the
areas of oncology, hematology, and ophthalmology, as well as diagnostic imaging equipment and
contrast agents. The Consumer Health segment offers nonprescription over-the-counter medicines,
medical products, cosmetics, and other self-care solutions in the categories of dermatology,
nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cough
and cold.
The company is a component of the Euro Stoxx 50 stock market index. Werner Baumann has been
CEO since 2016.
Q3 2020 Sales: 4229 M€ with Highest share of Consumer Health of 1205 M€

Therapeutic Focus: Bayer pharma provides pharmaceutical solutions for Cancer, Cardiovascular and
Kidney diseases, Eye conditions , Hemophyllia and other diseases. Apart from this, Bayer Provides
products in Women’s healthcare segment as well.

Products: Highlights 2020 Q3

1) Registered a strong increase in sales of oral anticoagulant Xarelto™
2) Sales of ophthalmology drug Eylea™ continued to edge higher against the previous year,
driven once again by the launch of Eylea™ prefilled syringes
3) Sales of cancer drug Nexavar™ fell substantially, mainly due to a decline in volumes in the
United States as a result of strong competition.
4) Registered significant sales gains for Aspirin™ Cardio, product for secondary prevention of
heart attacks
5) Cancer drug Stivarga™ continued to deliver substantial sales gains

Marketing:
Bayer adopted a new operational model in 2019 that aims to provide customers with the products,
services, and information they need to improve their quality of life by taking greater responsibility
for their daily health. Bayer is accelerating organic growth across attractive categories, geographies,
channels and brands and strive to transfer prescriptions and active ingredients to non-prescription
status to heighten their consumer-and customer-centric approach.

Main competitors:
Sun Pharma, Lupin, Cipla, Aurobindo Pharm, Cadila Health, Ranbaxy Labs, GlaxoSmithKline Plc.,
Johnson & Johnson, Abbott Laboratories, Novartis AG, Pfizer Inc.
Philosophy/mission

“At Bayer, the work we do changes lives. We are pursuing Science for a Better Life—not only for our
stakeholders, but to benefit everyone. Our vision “Health for all, Hunger for none” articulates what
we strive for.”

The patient comes first: For Bayer, patients' health always comes first. Exchanging ideas and
information with patient organizations on the basis of mutual trust. Such cooperation helps us to
understand the needs of patients as they come to terms with their illness. This enables to gear the
research and development to these needs and to continue working on improved, new drugs and
therapies. Bayer cooperates with patient organizations in all kinds of therapeutic areas.

CSR initiatives

1) Bayer supports leading organizations in the fight against neglected tropical diseases by
providing active ingredients free of charge.
2) The World Health Organization (WHO) uses medicines to treat Chagas disease, which is
widespread in Latin America, and African sleeping sickness. In partnership with the Drugs for
Neglected Diseases initiative (DNDi), Bayer is examining whether the active ingredient
etoposide (originally from the Japanese company Astellas) could be used to treat people
with river blindness.
3) Bayer is also currently developing a new formulation of the active ingredient nifurtimox in
order to test a more individualized dosage. This should simplify the treatment of children,
who are especially vulnerable to Chagas disease.